CLINICAL EVALUATION OF CEFTAZIDIME IN THE TREATMENT OF PEDIATRIC INFECTIONS

Ceftazidime (CAZ) was evaluated for its safety and efficacy in 31 children. Of the 25 confirmed bacterial infections, 23 were cured by the CAZ therapy (efficacy rate, 92%). CAZ was assessed as effective in acute pharyngitis with vomitings (4), acute laryngitis (1), pneumonia (8), urinary tract infec...

Full description

Saved in:
Bibliographic Details
Published in:Japanese journal of antibiotics 1984/03/25, Vol.37(3), pp.363-376
Main Authors: KIM, BOSU, MEGURO, HIDENORI, ARIMASU, OSAMU, MASHIKO, JIN, OHNARI, SHIGERU, TAGAYA, MITSURU, SAKAMOTO, MITSUNORI, FUJII, RYOCHI
Format: Article
Language:Japanese
Subjects:
Adolescent
Age Factors
Bacteria - isolation & purification
Bacterial Infections - drug therapy
Bacterial Infections - microbiology
Ceftazidime
Cephalosporins - adverse effects
Cephalosporins - metabolism
Cephalosporins - therapeutic use
Child
Child, Preschool
Drug Evaluation
Female
Half-Life
Humans
Infant
Infant, Newborn
Kinetics
Male
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Ceftazidime (CAZ) was evaluated for its safety and efficacy in 31 children. Of the 25 confirmed bacterial infections, 23 were cured by the CAZ therapy (efficacy rate, 92%). CAZ was assessed as effective in acute pharyngitis with vomitings (4), acute laryngitis (1), pneumonia (8), urinary tract infections (5), acute gastroenteritis (1), infection accompanying acute leukemia (septicemia suspected)(1), acute purulent meningitis (2) and abscess of the lateral cervical cyst (1). The main pathogens which responded to CAZ were H. influenzae, S. pyogenes, E. coli and P. aeruginosa. As adverse events, mild melena with prolonged prothrombin time (1) was found to be associated with the CAZ therapy. Half-life of the CAZ serum level was 0.97±0.10 hours, and urinary excretion was high. Penetration into the CSF in 2 cases of acute purulent meningitis was satisfactory. The data suggest that CAZ is a safe and effective injectable antibiotic when used in children with infections of CAZ-susceptible bacteria including P. aeruginosa.
ISSN:0368-2781
2186-5477
DOI:10.11553/antibiotics1968b.37.363